Atrasentan: A rationally designed targeted therapy for cancer

Drugs of Today

Volumn 42, Issue 5, 2006, Pages 299-312

  Jimeno, Antonio ^a   Carducci, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; BIOLOGICAL MARKER; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; FEXOFENADINE; KETOCONAZOLE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; ORGANIC ANION TRANSPORTER; PACLITAXEL; PHENYTOIN; RIFAMPICIN; WARFARIN; WORTMANNIN;

ANGIOGENESIS; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; BONE DEVELOPMENT; CANCER GROWTH; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DEREGULATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DYSPNEA; EDEMA; FOOD DRUG INTERACTION; HEADACHE; HEMODILUTION; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; NAUSEA; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHARMACOGENOMICS; PROSTATE CANCER; PULMONARY HYPERTENSION; REVIEW; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENDOTHELIN-1; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33745548413     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.5.973590     Document Type: Review

References (66)

1. Gronberg, H. Prostate cancer epidemiology. Lancet 2003, 361: 859-64.
2. Mahler, C., Denis, L.J. Hormone refractory disease. Semin Surg Oncol 1995, 11: 77-83.
3. Tannock, I.F., de Wit, R., Berry, W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351: 1502-12.
4. Petrylak, D.P., Tangen, C.M., Hussain, M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351: 1513-20.
5. Fox, E., Curt, G.A., Balis, F.M. Clinical trial design for target-based therapy. Oncologist 2002, 7: 401-9.
6. Rubin, S.A., Levin, E.R. Clinical review 53: The endocrinology of vasoactive peptides: Synthesis to function. J Clin Endocrinol Metab 1994, 78: 6-10.
7. Bremnes, T., Paasche, J.D., Mehlum, A., Sandberg, C., Bremnes, B., Attramadal, H. Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 2000, 275: 17596-604.
8. Levin, E.R. Endothelins. N Engl J Med 1995, 333: 356-63.
9. Gray, G.A., Webb, D.J. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996, 72: 109-48.
10. Bagnato, A., Natali, P.G. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004, 2: 16.
11. Obara, K., Koide, M., Ishikawa, T., Tanabe, Y., Nakayama, K. Protein kinase C delta but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery. J Cardiovasc Pharmacol 2000, 36: S120-S121.
12. Daub, H., Weiss, F.U., Wallasch, C., Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996, 379: 557-60.
13. Jiang, Z.Y., Zhou, Q.L., Chatterjee, A. et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999, 48: 1120-30.
14. Battistini, B., Chailler, P., D'Orleans-Juste, P., Briere, N., Sirois, P. Growth regulatory properties of endothelins. Peptides 1993, 14: 385-99.
15. Vacca, F., Bagnato, A., Catt, K.J., Tecce, R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000, 60: 5310-7.
16. Clarke, J.G., Benjamin, N., Larkin, S.W., Webb, D.J., Davies, G.J., Maseri, A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989, 257: H2033-5.
17. Remuzzi, G., Perico, N., Benigni, A. New therapeutics that antagonize endothelin: Promises and frustrations. Nat Rev Drug Discov 2002, 1: 986-1001.
18. Touyz, R.M., Schiffrin, E.L. Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003, 81: 533-41.
19. Nelson, J., Bagnato, A., Battistini, B., Nisen, P. The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003, 3: 110-6.
20. Rosano, L., Spinella, F., Di Castro, V et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005, 65: 11649-57.
21. Nelson, J.B., Hedican, S.P., George, D.J. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1: 944-9.
22. Nelson, J.B., Chan-Tack, K., Hedican, S.P. et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996, 56: 663-8.
23. Papandreou, C.N., Usmani, B., Geng, Y. et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998, 4: 50-7.
24. Nelson, J.B., Lee, W.H., Nguyen, S.H. et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997, 57: 35-7.
25. Usmani, B.A., Harden, B., Maitland, N.J., Turner, A.J. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond) 2002, 103 (Suppl. 48): 314S-7.
26. Salani, D., Di Castro, V., Nicotra, M.R. et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000, 157: 1537-47.
27. Godara, G., Cannon, G.W., Cannon, G.M. Jr., Bies, R.R., Nelson, J.B., Pflug, B.R. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005, 65: 27-34.
28. Kopetz, E.S., Nelson, J.B., Carducci, M.A. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 2002, 20: 173-82.
29. Eberl, L.P., Valdenaire, O., Saintgiorgio, V., Jeannin, J.F., Juillerat-Jeanneret, L. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer 2000, 86: 182-7.
30. Del Bufalo, D., Di Castro, V., Biroccio, A. et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: Requirement for Akt activation. Mol Pharmacol 2002, 61: 524-32.
31. Nelson, J.B., Udan, M.S., Guruli, G., Pflug, B.R. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005, 7: 631-7.
32. Del Bufalo, D., Di Castro, V., Biroccio, A. et al. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002, 103 (Suppl. 48): 302S-5.
33. Rosano, L., Varmi, M., Salani, D. et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001, 61: 8340-6.
34. Rosano, L., Salani, D., Di Castro, V., Spinella, F., Natali, P.G., Bagnato, A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 2002, 103 (Suppl. 48): 306S-9.
35. Rosano, L., Spinella, F., Di Castro, V. et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003, 163: 753-62.
36. Bagnato, A., Rosano, L., Spinella, F., Di Castro, V., Tecce, R., Natali, P.G. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004, 64: 1436-43.
37. Spinella, F., Rosano, L., Di Castro, V., Nicotra, M.R., Natali, P.G., Bagnato, A. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 2003, 278: 41294-301.
38. Salani, D., Taraboletti, G., Rosano, L. et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000, 157: 1703-11.
39. Knowles, J., Loizidou, M., Taylor, I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005, 3: 309-14.
40. Spinella, F., Rosano, L., Di Castro, V., Natali, P.G., Bagnato, A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem 2002, 277: 27850-5.
41. Spinella, F., Rosano, L., Di Castro, V., Nicotra, M.R., Natali, P.G., Bagnato, A. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin A receptor in human ovarian carcinoma cells. Clin Cancer Res 2004, 10: 4670-9.
42. Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D.G., Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42: 73-8.
43. Pruthi, R.S., Derksen, J.E., Moore, D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004, 93: 275-8.
44. Nelson, J.B., Nguyen, S.H., Wu-Wong, J.R. et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999, 53: 1063-9.
45. Chiao, J.W., Moonga, B.S., Yang, Y.M. et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000, 83: 360-5.
46. Yin, J.J., Mohammad, K.S., Kakonen, S.M. et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100: 10954-9.
47. Guise, T.A., Yin, J.J., Mohammad, K.S. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003, 97: 779-84.
48. Pomonis, J.D., Rogers, S.D., Peters, C.M., Ghilardi, J.R., Mantyh, P.W. Expression and localization of endothelin receptors: Implications for the involvement of peripheral glia in nociception. J Neurosci 2001, 21: 999-1006.
49. Jarvis, M.F., Wessale, J.L., Zhu, C.Z. et al. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol 2000, 388: 29-35.
50. Yuyama, H., Koakutsu, A., Fujiyasu, N. et al. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 2004, 44(Suppl. 1): S479-82.
51. Yuyama, H., Koakutsu, A., Fujiyasu, N. et al. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol 2004, 492: 177-82.
52. Khodorova, A., Navarro, B., Jouaville, L.S. et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 2003, 9: 1055-61.
53. Peters, C.M., Lindsay, T.H., Pomonis, J.D. et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004, 126: 1043-52.
54. Wu-Wong, J.R., Dixon, D.B., Chiou, W.J. et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: In vitro studies. Clin Sci (Lond) 2002, 103(Suppl. 48): 107S-11.
55. Zhu, T., Andre, A., Facey, I. et al. Effect of ketoconazole (KET) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN). 40th American Society of Clinical Oncology, Annual Meeting, New Orleans 2004, Abst. 4727.
56. Xiong, H., Jankowski, J., Ashbrenner, E. et al. Effect of rifampin (RIF) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN). 40th American Society of Clinical Oncology, Annual Meeting, New Orleans 2004, Abst. 4728.
57. Klein, C.E., Schroeder, M.C., Facey, I. et al Effect of atrasentan (ABT-627, ATN) on the pharmacokinetics (PK) of fexofenadine (FEX). 40th American Society of Clinical Oncology, Annual Meeting, New Orleans 2004, Abst. 4723.
58. Katz, D.A., Grimm, D.R., Carr, R. et al. Pharmacogenetic metaanalysis suggests that atrasentan is an organic anion transport protein C substrate. Clin Pharm Ther 2004, 75: 94.
59. Samara, E., Dutta, S., Cao, G., Granneman, G.R., Dordal, M.S., Padley, R.J. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol 2001, 41: 397-403.
60. Carducci, M.A., Nelson, J.B., Bowling, M.K. et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 2002, 20: 2171-80.
61. Zonnenberg, B.A., Groenewegen, G., Janus, T.J. et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003, 9: 2965-72.
62. Ryan, C.W., Vogelzang, N.J., Vokes, E.E. et al. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res 2004, 10: 4406-11.
63. Carducci, M.A., Nelson, J.B., F. Saad, F. et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. 40th American Society of Clinical Oncology, Annual Meeting, New Orleans 2004, Abst. 4508.
64. Carducci, M.A., Padley, R.J., Breul, J. et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21: 679-89.
65. Nelson, J.B., Nabulsi, A.A., Vogelzang, N.J. et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003, 169: 1143-9.
66. Carducci, M.A., Nelson, J.B., Vogelzang, N.J., Mulani, P. Determination of Clinically Meaningful Change (CMC) for Functional Assessment of Cancer Treatment-Prostate (FACT-P). American Society of Clinical Oncology Prostate Cancer Symposium, Orlando 2005, Abst. 275.